A single-center, open label, randomized, controlled study of hydroxychloroquine sulfate in the treatment of low risk PLA<sub>2</sub>R-associated membranous nephropathy.

导出 OA

翻译打印收藏纠错

作者： Mei,Mei ^[1] ; Jun,Zeng ^[2] ; Zhengyang,Liu ^[2] ; Li,Gong ^[2] ; Li,Fang ^[3] ; Quan,Hu ^[4] ; Shaofen,Huang ^[4] ; Liyin,Chai ^[2] ; Xinqing,Chen ^[2] ; Haili,Sun ^[2] ; Sha,Xiang ^[2] ; Chaolin,Wen ^[2] ; Bingbing,Shen ^[5]

作者单位： Department of Nephrology & Rheumatology, People's Hospital of Shapingba District, Chongqing University Shapingba Hospital, School of Medicine，Chongqing University, Chongqing, China.;Department of Nephrology, The First Hospital Affiliated to Army Medical University, Chongqing, China. ^[1] Department of Nephrology, Chongqing Emergency Medical Center, Chongqing University Central Hospital, School of Medicine,Chongqing University, Chongqing, China. ^[2] Department of Nephrology, The First Hospital Affiliated to Army Medical University, Chongqing, China. ^[3] Department of Nephrology & Rheumatology, People's Hospital of Shapingba District, Chongqing University Shapingba Hospital, School of Medicine，Chongqing University, Chongqing, China. ^[4] Department of Nephrology, The First Hospital Affiliated to Army Medical University, Chongqing, China. shenbingbing@cqu.edu.cn.;Department of Nephrology, Chongqing Emergency Medical Center, Chongqing University Central Hospital, School of Medicine,Chongqing University, Chongqing, China. shenbingbing@cqu.edu.cn. ^[5]

关键词 Hydroxychloroquine sulfate Low risk PLA2R-associated membranous nephropathy